Clinical Trial: Phase I Trial of RBD4059 in Chinese Healthy Participants

U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07930767) titled 'Phase I Trial of RBD4059 in Chinese Healthy Participants' on Nov. 05.

Brief Summary: This is a randomized, double-blind, sponsor-open, placebo-controlled, single-dose phase I study.

The goal of this clinical trial is to evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and tolerability of RBD4059 in Chinese healthy participants.

Participants will receive single doses of RBD4059 or placebo, and need about 16 visits for checkups and tests until End of trial.

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: DRUG: RBD4059

Subcutaneously Administered RBD4059 in Healthy Participants....